Heron Therapeutics
HRTX
59 hedge funds and large institutions have $202M invested in Heron Therapeutics in 2014 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 28 increasing their positions, 12 reducing their positions, and 13 closing their positions.
133% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 12
0% more call options, than puts
Call options by funds: $8K | Put options by funds: $8K
14% less funds holding
Funds holding: 69 → 59 (-10)
38% less capital invested
Capital invested by funds: $327M → $202M (-$125M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
69% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$5.05M |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$1.74M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$1.17M |
| 4 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$747K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$723K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$6.98M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$5.62M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$4.68M |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$924K |
| 5 |
Tudor Investment Corp
Stamford,
Connecticut
|
-$503K |
HRTX Hedge Fund Activity: Q3 2014 in Review
59 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q3 2014, worth a combined $202M — down 38% from $327M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of HRTX and 4 opened new positions — a net loss of 9 holders — while 12 trimmed existing stakes and 28 added.
The largest buyer was Franklin Resources, adding an estimated $5.05M. The largest seller was Perceptive Advisors, cutting an estimated $6.98M.
- 59 institutional investors held Heron Therapeutics (HRTX) as of Q3 2014, down from 69 in Q2 2014.
- Funds reported $202M of Heron Therapeutics stock for Q3 2014, down 38% quarter-over-quarter.
- 4 funds opened new Heron Therapeutics positions in Q3 2014 and 13 closed out, a net change of -9 holders.
- The largest Heron Therapeutics buyer in Q3 2014 was Franklin Resources, an estimated $5.05M added.
- The largest Heron Therapeutics seller in Q3 2014 was Perceptive Advisors, an estimated $6.98M sold.
Based on aggregated 13F filings for Q3 2014.